World's Best Scientists 2026 revealed!
Mark A. Brockman

Mark A. Brockman

D-Index & Metrics

Immunology

D-Index
57
Citations
10253
World Ranking
3639
National Ranking
95

Mark A. Brockman publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark A. Brockman sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 195 publications — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mark A. Brockman D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark A. Brockman sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 57 D-Index — 28th percentile

28% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 1963 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Mark A. Brockman is affiliated with Simon Fraser University in Canada. Their research primarily focuses on medicine, with significant contributions in immunology and microbiology.

The main subfields of study by Mark A. Brockman include infectious diseases, virology, immunology, health, and public health, environmental and occupational health. The principal topics of their work cover a range of issues related to infectious diseases and public health, notably:

  • SARS-CoV-2 and COVID-19 research
  • COVID-19 clinical research studies
  • HIV research and treatment
  • Vaccine coverage and hesitancy
  • HIV/AIDS drug development and treatment
  • HIV/AIDS research and interventions
  • COVID-19 impact on reproduction

Recent papers authored or coauthored by Brockman include the following:

  • "African-led health research and capacity building- is it working?" (2020), published in BMC Public Health
  • "Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults" (2021), published in The Journal of Infectious Diseases
  • "Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy" (2022), published in npj Vaccines
  • "People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses" (2022), published in The Journal of Infectious Diseases
  • "Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose" (2022), published in The Journal of Infectious Diseases

Mark A. Brockman frequently publishes in several venues including bioRxiv (Cold Spring Harbor Laboratory), AIDS, The Journal of Infectious Diseases, Viruses, and Frontiers in Reproductive Health.

Frequent coauthors collaborating with Brockman include:

  • Zabrina L. Brumme
  • Hope R. Lapointe
  • Chanson J. Brumme
  • Francis Mwimanzi
  • Julio Montaner

The scientist has also been recognized as a Fellow of the American Association for the Advancement of Science (AAAS) since 1963.

Best Publications

  • Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.

    Daniel E Kaufmann;Daniel G Kavanagh;Florencia Pereyra;Florencia Pereyra;John J Zaunders

  • Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associated with a dramatic reduction in human immunodeficiency virus type 1 replication.

    Arne Schneidewind;Mark A. Brockman;Mark A. Brockman;Ruifeng Yang;Rahma I. Adam

  • IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells.

    Mark A. Brockman;Mark A. Brockman;Douglas S. Kwon;Douglas S. Kwon;Douglas S. Kwon;Daniel P. Tighe;David F. Pavlik

  • Escape and Compensation from Early HLA-B57-Mediated Cytotoxic T-Lymphocyte Pressure on Human Immunodeficiency Virus Type 1 Gag Alter Capsid Interactions with Cyclophilin A

    Mark A. Brockman;Arne Schneidewind;Matthew Lahaie;Aaron Schmidt;Aaron Schmidt

  • TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection

    Huabiao Chen;Zaza M Ndhlovu;Zaza M Ndhlovu;Dongfang Liu;Lindsay C Porter

  • HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphocyte Recognition.

    Toshiyuki Miura;Mark A. Brockman;Arne Schneidewind;Michael Lobritz

  • Herpes simplex virus.

    Travis J Taylor;Mark A Brockman;Elizabeth E McNamee;David M Knipe

  • HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins

    Zabrina L. Brumme;Zabrina L. Brumme;Mina John;Jonathan M. Carlson;Chanson J. Brumme

  • Responsiveness of HIV-specific CD4 T cells to PD-1 blockade

    Filippos Porichis;Douglas S. Kwon;Douglas S. Kwon;Douglas S. Kwon;Jennifer Zupkosky;Daniel P. Tighe

  • Structural and Functional Constraints Limit Options for Cytotoxic T-Lymphocyte Escape in the Immunodominant HLA-B27-Restricted Epitope in Human Immunodeficiency Virus Type 1 Capsid

    Arne Schneidewind;Mark A. Brockman;Mark A. Brockman;John Sidney;Yaoyu E. Wang

  • HIV Increases HCV Replication in a TGF-β1–Dependent Manner

    Wenyu Lin;Ethan M. Weinberg;Andrew W. Tai;Lee F. Peng

  • Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults

    Unknown

  • Early Selection in Gag by Protective HLA Alleles Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in Chronic Infection

    Mark A. Brockman;Mark A. Brockman;Mark A. Brockman;Zabrina L. Brumme;Zabrina L. Brumme;Zabrina L. Brumme;Chanson J. Brumme;Chanson J. Brumme;Toshiyuki Miura;Toshiyuki Miura

  • Attenuation of multiple Nef functions in HIV-1 elite controllers.

    Philip Mwimanzi;Philip Mwimanzi;Tristan J Markle;Eric Martin;Yoko Ogata

  • HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying gag-protease from Elite Controllers of Human Immunodeficiency Virus Type 1

    Toshiyuki Miura;Mark A. Brockman;Zabrina L. Brumme;Chanson J. Brumme

  • Genetic Characterization of Human Immunodeficiency Virus Type 1 in Elite Controllers: Lack of Gross Genetic Defects or Common Amino Acid Changes

    Toshiyuki Miura;Mark A. Brockman;Chanson J. Brumme;Zabrina L. Brumme

  • Humoral response to herpes simplex virus is complement-dependent

    Xavier J. Da Costa;Mark A. Brockman;Elisabeth Alicot;Minghe Ma

  • HIV-1 Vpu Mediates HLA-C Downregulation.

    Richard Apps;Gregory Q. Del Prete;Pramita Chatterjee;Abigail Lara

  • Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers

    Toshiyuki Miura;Zabrina L. Brumme;Mark A. Brockman;Pamela Rosato

  • Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy

    Unknown

  • Selective Depletion of High-Avidity Human Immunodeficiency Virus Type 1 (HIV-1)-Specific CD8+ T Cells after Early HIV-1 Infection

    Mathias Lichterfeld;Xu G. Yu;Stanley K. Mui;Katie L. Williams

  • HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte recognition (Journal of Virology (2009) 83, 6, (2743-2755))

    Toshiyuki Miura;Mark A. Brockman;Arne Schneidewind;Michael Lobritz

Frequent Co-Authors

Zabrina L. Brumme
Zabrina L. Brumme Simon Fraser University
Bruce D. Walker
Bruce D. Walker Harvard University
Thumbi Ndung'u
Thumbi Ndung'u University of KwaZulu-Natal
Chanson J. Brumme
Chanson J. Brumme University of British Columbia
Philip J. R. Goulder
Philip J. R. Goulder University of Oxford
Jonathan M. Carlson
Jonathan M. Carlson Microsoft (United States)
Florencia Pereyra
Florencia Pereyra Harvard University
Todd M. Allen
Todd M. Allen Harvard University
Glenda Gray
Glenda Gray South African Medical Research Council
Alicja Trocha
Alicja Trocha Ragon Institute of MGH, MIT and Harvard

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related online degrees and career pathways can broaden professional opportunities and enhance expertise. Many students consider advancing toward specialized nursing roles, such as psychiatric-mental health nurse practitioners. Programs offering the top online pmhnp programs provide excellent clinical placement rates, ensuring practical experience alongside theoretical knowledge.

Cost is a significant factor for many students. Fortunately, some of the cheapest online pmhnp programs make advanced education more accessible without compromising quality. These affordable options enable aspiring nurse practitioners to develop critical skills for careers in immunology-related healthcare settings.

Understanding potential earnings is also crucial when selecting a career path. According to data on how much do dnps make, Doctor of Nursing Practice graduates can expect competitive salaries that reflect their advanced training and specialization.

For current nurse practitioners aiming to pivot toward acute care, pursuing acute care np certification can be an important step. This certification opens doors to specialized clinical roles, complementing immunology expertise in high-intensity healthcare environments.

Best Scientists Citing Mark A. Brockman

Trending Scientists

Recently Published Articles